Literature DB >> 16029022

A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.

Dimitrios Krikorian1, Eugenia Panou-Pomonis, Chryssa Voitharou, Constantinos Sakarellos, Maria Sakarellos-Daitsiotis.   

Abstract

A multifunctional carrier combining B/T cell epitopes (i), a built-in vaccine adjuvant (ii), and a universal T cell epitope (iii) for the construction of potent and specific immunogenic conjugates is presented. The IL-1beta(163-171) fragment known to reproduce the immunostimulatory and adjuvant effects of the whole IL-1beta without possessing any of the pro-inflammatory properties of IL-1beta was covalently anchored to the N-terminus of the Sequential Oligopeptide Carrier, SOC(n), formed by the repeating tripeptide unit Lys-Aib-Gly. A promiscuous T cell epitope derived from the tetanus toxin, TT(593-599), was also positioned in the carboxy terminus of SOC(n) as a universal immunogen to provide broad immunogenicity. Selected B/T cell epitopes from the Sm and La/SSB autoantigens, against which is directed the humoral autoimmunity in patients with systemic lupus erythematosus and Sjögren's Syndrome, respectively, were coupled to the Lys-N(epsilon)H2 groups of the carrier, and the formulated constructs were administered in animals following the conventional immunization protocol of complete/incomplete Freund's adjuvant. The induced immune responses were compared with that produced when the Sm- and La/SSB-reconstituted immunogenic conjugates were injected alone. High titers of specific antibodies recognizing the priming construct, as well as the cognate autoantigen, were obtained when administered alone without the assistance of Freund's adjuvant. It is concluded that our approach provides the conceptual and experimental framework for the development of multifunctional immunogenic conjugates eliciting enhanced, specific, and prolonged humoral response for usage as human vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16029022     DOI: 10.1021/bc049703m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  6 in total

1.  A candidate dual vaccine against influenza and noroviruses.

Authors:  Ming Xia; Ming Tan; Chao Wei; Weiming Zhong; Leyi Wang; Monica McNeal; Xi Jiang
Journal:  Vaccine       Date:  2011-08-11       Impact factor: 3.641

2.  Robust immune responses elicited by a fully synthetic three-component vaccine.

Authors:  Sampat Ingale; Margreet A Wolfert; Jidnyasa Gaekwad; Therese Buskas; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2007-09-02       Impact factor: 15.040

3.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

Review 4.  Immunotherapy for cancer: synthetic carbohydrate-based vaccines.

Authors:  Therese Buskas; Pamela Thompson; Geert-Jan Boons
Journal:  Chem Commun (Camb)       Date:  2009-07-22       Impact factor: 6.222

Review 5.  Recent Advances in Subunit Vaccine Carriers.

Authors:  Abhishek Vartak; Steven J Sucheck
Journal:  Vaccines (Basel)       Date:  2016-04-19

6.  Mannose-Modified Multi-Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells.

Authors:  Zhipeng Dong; Qiyan Wang; Ming Huo; Nanxia Zhang; Bingxia Li; Hongmei Li; Yisong Xu; Meng Chen; Hao Hong; Yue Wang
Journal:  ChemistryOpen       Date:  2019-07-12       Impact factor: 2.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.